Skip to main content

Cardiac Failure

0
Pipeline Programs
7
Companies
6
Clinical Trials
2 recruiting
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
0
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

7 companies ranked by most advanced pipeline stage

iNova Pharmaceuticals
iNova PharmaceuticalsAustralia - Chatswood
2 programs
OPtimal Adult Heart Transplant Immunosuppression With MicroRNA LevelsN/A1 trial
Optimal Pediatric Heart Transplant Immunosuppression With MicroRNAsN/A1 trial
Active Trials
NCT06939751Recruiting250Est. Jan 2032
NCT06532890Recruiting150Est. Oct 2029
Angeles Therapeutics
Angeles TherapeuticsCA - Los Angeles
1 program
Cova PatchN/A
Baxter International
1 program
Cova PatchN/A
Baxter
BaxterCosta Rica - Cartago
1 program
Cova PatchN/A
Colorado Therapeutics
Colorado TherapeuticsCO - Louisville
1 program
Heart Failure Disease Management ProgramN/A1 trial
Active Trials
NCT01822912Completed713Est. Mar 2019
Bristol Myers Squibb
1 program
BMS-986224PHASE_12 trials
Active Trials
NCT03634969Completed50Est. Apr 2019
NCT03563950Completed42Est. Jul 2018
Takeda
TakedaTOKYO, Japan
1 program
Ferric carboxymaltosePHASE_41 trial
Active Trials
NCT03871699Unknown20Est. Feb 2021

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
2027
2028
2029
2030
2031
TakedaFerric carboxymaltose
Bristol Myers SquibbBMS-986224
Bristol Myers SquibbBMS-986224
iNova PharmaceuticalsOPtimal Adult Heart Transplant Immunosuppression With MicroRNA Levels
iNova PharmaceuticalsOptimal Pediatric Heart Transplant Immunosuppression With MicroRNAs
Colorado TherapeuticsHeart Failure Disease Management Program

Clinical Trials (6)

Total enrollment: 1,225 patients across 6 trials

NCT03871699TakedaFerric carboxymaltose

Ferric Carboximaltose on Intra-myocardial Iron Load in Patients With Heart Failure

Start: Aug 2019Est. completion: Feb 202120 patients
Phase 4Unknown
NCT03634969Bristol Myers SquibbBMS-986224

An Investigational Study to Evaluate Experimental Medication BMS-986224 in Renally Impaired Participants

Start: Aug 2018Est. completion: Apr 201950 patients
Phase 1Completed
NCT03563950Bristol Myers SquibbBMS-986224

An Investigational Study to Evaluate the Effect of Rifampin on the Singe Dose of Experimental Medication BMS-986224 in Healthy Participants

Start: Jun 2018Est. completion: Jul 201842 patients
Phase 1Completed
NCT06939751iNova PharmaceuticalsOPtimal Adult Heart Transplant Immunosuppression With MicroRNA Levels

OPtimal Adult Heart Transplant Immunosuppression With MicroRNA Levels

Start: Oct 2025Est. completion: Jan 2032250 patients
N/ARecruiting
NCT06532890iNova PharmaceuticalsOptimal Pediatric Heart Transplant Immunosuppression With MicroRNAs

Optimal Pediatric Heart Transplant Immunosuppression With MicroRNAs

Start: Feb 2025Est. completion: Oct 2029150 patients
N/ARecruiting
NCT01822912Colorado TherapeuticsHeart Failure Disease Management Program

Heart Failure Management Program Versus Usual Care

Start: Jan 2013Est. completion: Mar 2019713 patients
N/ACompleted

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

2 actively recruiting trials targeting 1,225 patients
7 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.